Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Lucid Diagnostics, Fred Hutchinson Cancer Research Center Ink Esophageal Cancer Biomarker Deal

Lucid Diagnostics, Fred Hutchinson Cancer Research Center Ink Esophageal Cancer Biomarker Deal

Feb 20, 2020
|
staff reporter

NEW YORK – Lucid Diagnostics announced Thursday it has entered a research agreement with the Fred Hutchinson Cancer Research Center to evaluate the center's Barrett's Esophagus progression biomarkers using Lucid's EsoCheck Esophageal Cell Collection Device.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

A Start

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

Just Go 'Round the CDC

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

Student Visa Directive Rescinded

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

Cell Studies on Blood Features of Severe COVID-19 Cases, Infection-Related Phosphorylation Shifts, More

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.

What's Popular?

In Business News

  1. Illumina Acquires French Genomic Data-Compression Startup Enancio

  2. Deep Longevity Closes Series A, Partners With Human Longevity

  3. Berkeley Lights to Raise up to $153M in IPO

  4. Thermo Fisher Scientific Increases Offer for Qiagen to €43 Per Share

  5. FDA Grants EUA to KogeneBiotech, Trax Management, and Compass Laboratory Coronavirus Tests

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.